Source comparison
Women 55+ Postmenopause Sermorelin Protocol Comparison
Starting Dose 100–150mcg nightly 200–250mcg nightly 150–200mcg nightly Postmenopausal women require 30–50% higher doses due to estrogen withdrawal reducing hepatic GH receptor density Target IGF-1 Range 180–250 ng/mL 150–220 ng/mL 200–280 ng/mL Lower target fo
This comparison does not assign a generated winner or score.
- Starting Dose
- 100–150mcg nightly
- 200–250mcg nightly
- 150–200mcg nightly
- Postmenopausal women require 30–50% higher doses due to estrogen withdrawal reducing hepatic GH receptor density
- Target IGF-1 Range
- 180–250 ng/mL
- 150–220 ng/mL
- 200–280 ng/mL
- Lower target for postmenopausal women reduces breast tissue proliferation risk while maintaining metabolic benefit
- Frequency
- 5–7 nights weekly
- 5–6 nights weekly
- Continuous nightly dosing in all groups risks receptor downregulation. Periodic off-nights preserve sensitivity
- Monitoring Interval
- Every 12 weeks
- Every 8–12 weeks
- More frequent monitoring in early postmenopause detects non-responders faster and allows dose adjustment before side effects emerge
- Common Dose-Limiting Side Effect
- Mild fluid retention at >200mcg
- Joint pain, edema at >300mcg
- Carpal tunnel symptoms at >250mcg
- Postmenopausal women show lowest tolerance for supraphysiological IGF-1. Dose ceiling is effectively 300mcg